Clinical trial • Phase III • Immunology
budoprutug (TNT119) for Systemic lupus erythematosus
Phase III trial of budoprutug (TNT119) for Systemic lupus erythematosus. 13 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Systemic lupus erythematosus
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 25-03-2025
- First CTIS Authorization Date
- 30-06-2025
Trial design
Phase III trial across 3 sites in Greece, Bulgaria, Romania and others.
- Target Sample Size
- 13
Eligibility
Recruits 13 isVulnerablePopulationSelected: false. No additional information on vulnerable populations, consent, or assent available in the record..
- Vulnerable Population
- isVulnerablePopulationSelected: false. No additional information on vulnerable populations, consent, or assent available in the record.
Recruitment
- Planned Sample Size
- 13
- Recruitment Window Months
- 25
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 13
Greece
- Earliest CTIS Part Ii Submission Date
- 05-05-2025
- Latest Decision Or Authorization Date
- 30-06-2025
- Processing Time Days
- 56
- Number Of Sites
- 3
- Number Of Participants
- 3
Sites
- Site Name
- Ippokratio General Hospital Of Thessaloniki
- Department Name
- Nephrology Department
- Contact Person Name
- Maria Stangou
- Contact Person Email
- mstangou@auth.gr
- Site Name
- Geniko Nosokomeio Thessalonikis George Papanikolaou
- Department Name
- Nephrology Department
- Contact Person Name
- Gerasimos Bamichas
- Contact Person Email
- gbamihas@gmail.com
- Site Name
- Laiko General Hospital Of Athens
- Department Name
- A’ Department of Propaeudeutic Internal Medicine
- Contact Person Name
- Maria Tektonidou
- Contact Person Email
- mtektonidou@gmail.com
Bulgaria
- Number Of Sites
- 0
Romania
- Number Of Sites
- 0
Spain
- Number Of Sites
- 0
Sponsor
Primary sponsor
- Full Name
- Climb Bio Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- budoprutug (TNT119)
Related trials
Other published trials that may interest you.